Cushing’s Disease in Pregnancy and Cabergoline Use: Obstetric and Neonatal Outcomes
Download PDF


Cushing’s syndrome



Submitted : 2023-04-15
Accepted : 2023-04-30
Published : 2023-05-15


Pregnancy in patients with Cushing’s disease (CD) is rare and is associated with significant maternal and fetal complications. We report a case of CD who achieved uncomplicated pregnancy and delivery after treatment with low-dose cabergoline. A 29-year-old woman was diagnosed with CD (adrenocorticotropic hormone-secreting macrotumor that causes displacement of the optic chiasm, infiltrates the right cavernous sinus, and engulfs the internal carotid artery) and underwent transsphenoidal surgery with incomplete tumor resection. After a year of clinical stability, her symptoms recurred, and cabergoline was initiated. During the treatment, the patient conceived, and the medication was suspended. In the first trimester, clinical and biochemical parameters indicate active CD, so cabergoline was reinstated at a low dose for the rest of the pregnancy. With the dopaminergic agonist, her clinical and laboratory parameters normalized, and the patient gave birth to a healthy girl at 38 weeks, within normal percentiles and without complications. Pregnancy in patients diagnosed with CD is a rare event, and the consequences of maternal-fetal exposure to hypercortisolism can be severe. Our experience with the use of cabergoline at low doses in a pregnant woman with CD contributes favorable data to the scarce existing literature reports, adding evidence on the safety profile of the drug in this population.


Sharma ST, Nieman LK, Feelders RA, 2015, Cushing’s Syndrome: Epidemiology and Developments in Disease Management. Clin Epidemiol, 7: 281–293.

Laway BA, Mir SA, 2013, Pregnancy and Pituitary Disorders: Challenges in Diagnosis and Management. Indian J Endocrinol Metab, 17(6): 996–1004.

Broder MS, Neary MP, Chang E, et al., 2015, Incidence of Cushing’s Syndrome and Cushing’s Disease in Commercially-Insured Patients < 65 Years Old in the United States. Pituitary, 18(3): 283–289.

Caimari F, Valassi E, Garbayo P, et al., 2017, Cushing’s Syndrome and Pregnancy Outcomes: A Systematic Review of Published Cases. Endocrine, 55(2): 555–563.

Lindsay JR, Jonklaas J, Oldfield EH, et al., 2005, Cushing’s Syndrome During Pregnancy: Personal Experience and Review of the Literature. J Clin Endocrinol Metab, 90(5): 3077–3083.

Dong D, Li H, Xiao H, 2015, The Diagnosis and Management of Cushing Syndrome During Pregnancy. J Obstet Gynaecol, 35(1): 94–96.

Abou-Samra AB, Pugeat M, Dechaud H, et al., 1984, Increased Plasma Concentration of N-Terminal Beta-Lipotrophin and Unbound Cortisol During Pregnancy. Clin Endocrinol (Oxf), 20(2): 221–228.

Ambroziak U, Kondracka A, Bartoszewicz Z, et al., 2015, The Morning and Late-Night Salivary Cortisol Ranges for Healthy Women May Be Used in Pregnancy. Clin Endocrinol (Oxf), 83(6): 774–778.

Nieman LK, Biller BM, Findling JW, et al., 2008, The Diagnosis of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 93(5): 1526–1540.

Fux Otta C, Cecenarro L, Estario ME, et al., 2015, Actualización en Endocrinología: Manejo de Las Prolactinomas Durante la Gestación [Update on Endocrinology: Management of Prolactinomas During Pregnancy]. Rev Fac Cien Med Univ Nac Cordoba, 72(3): 170–174.

Molitch ME, 2015, Endocrinology in Pregnancy: Management of the Pregnant Patient with a Prolactinoma. Eur J Endocrinol, 172(5): R205–R213.

Pivonello R, Ferone D, de Herder WW, et al., 2004, Dopamine Receptor Expression and Function in Corticotroph Pituitary Tumors. J Clin Endocrinol Metab, 89(5): 2452–2462.

Nakhleh A, Saiegh L, Reut M, et al., 2016, Cabergoline Treatment for Recurrent Cushing’s Disease During Pregnancy. Hormones (Athens), 15(3): 453–458.

Sek KS, Deepak DS, Lee KO, 2017, Use of Cabergoline for the Management of Persistent Cushing’s Disease in Pregnancy. BMJ Case Rep, 2017: bcr-2016-217855.

Feelders RA, Hofland LJ, 2013, Medical Treatment of Cushing’s Disease. J Clin Endocrinol Metab, 98(2): 425–438.